



OaCP

**THE NEXT LEADER IN MOLECULAR
DIAGNOSIS**

THE OACP A-TEAM



ENRICO DI OTO
CEO

BS, MD, PHD
17 YEARS IN CANCER
DIAGNOSIS
>15,000 TESTS
COMPLETED



ANDREA FAVIERE
MARKETING-SALES

MBA
> 10 YEARS IN
MARKETING



FRANCESCO VILLA
BUSINESS SUPPORT

MBA
> 10 YEARS IN
BUSINESS
MANAGEMENT



SIMONE DI GIACOMO
R&D MANAGER

BS,PHD
> 15 YEARS IN
MOLECULAR
BIOLOGY



MATTEO ALLEGRO
CCO

> 7 YEARS IN
COMMUNICATION



18 MILLION CANCERS DIAGNOSED IN THE WORLD YEARLY

In a post Covid Pandemic World a tsunami of diagnostic procedures will be required in Cancer detection

(-99,5% of Breast Cancer intervention,
-2,5M people screened, only in Italy, in 2020)

Traditional diagnostic tools lack efficiency in DNA alteration detections resulting in **increased costs and time** in diagnostic processing.

Lengthy response times to clinicians and patients caused by test backlogs leads to anxious times waiting for results.



CHEMICAL REAGENTS FOR ONCOLOGY

HELPING TO SAVE LIVES THROUGH REDUCED LABORATORY TEST TIME TO RESULTS

IMPROVE DNA REACTION
EFFICIENCY



50% Test *Cost* Reduction

97% Test *Time* Reduction

ISH (IN SITU HYBRIDISATION)

GOLD STANDARD LABORATORY TECHNIQUE FOR
DNA/RNA ALTERATIONS IDENTIFICATION




CE-IVD Approved products

APPLICATIONS: PRECISION MEDICINE COMPANION TESTS

PRODUCTS HAVE BEEN VALIDATED FOR:

- BREAST CANCER (HER-2, PDL1)
- LUNG CANCER (ALK, ROS, PDL1)
- GASTRIC CANCER (HER-2)
- LEUKEMIAS (BCR/ABL ...)
- TARGETED PIPELINE OF PRODUCTS....










IMPROVING CANCER PATIENTS' QUALITY OF LIFE

MARKET LANDSCAPE

MARKET TRENDS

- IN SITU HYBRIDIZATION IS THE **GOLD STANDARD** FOR PRECISION MEDICINE
- **USD 1B** GLOBAL MARKET OPPORTUNITY (CAGR 7.3%)
- RISE IN NEW TARGET THERAPIES IS DRIVING GROWTH

COMPETITION

	 OaCP	 Agilent Technologies	 Abbott
2 HOURS TEST			
COST REDUCTION			
NO NEW EQUIPMENT			

PATENT PROTECTION

FORMULATION + METHOD

SEVERAL APPLICATIONS IN THE DNA/RNA INDUSTRY

GRANTED IN

ITALY, THE EU, THE USA & CHINA



PENDING IN

INDIA



ONGOING REVENUES SINCE 2019

A GLOBAL DISTRIBUTION NETWORK

DISTRIBUTORS

LABS



HOSPITALS

5 PRODUCTS

98% GROSS MARGIN



4.720

68.324

2020: COVID OUTBREAK IMPACTS THE ONCOLOGY DIAGNOSTIC MARKET



CE-IVD COVID-19 RT-PCR
DIAGNOSTIC KIT

3,056 deaths

Hubei China

827 deaths

Italy

429 deaths

Iran

66 deaths

Korea, South

55 deaths

Spain

48 deaths

France France

31 deaths

Washington US

22 deaths

Henan China

16 deaths

Japan

13 deaths

China

50,318 recovered

Hubei China

99 recovered

Iran

1,289 recovered

Guangdong China

1,249 recovered

Henan China

1,197 recovered

Zhejiang China

1,045 recovered

Italy

999 recovered

Hunan China

984 recovered

Anhui China

934 recovered

Jiangxi China

734 recovered

Shandong China

China


2021: COVID-19 VARIANTS ARE RISING

MAIN DIAGNOSTIC TOOLS REQUIRE MULTIPLE PROCESSING STEPS:


- **CURRENT PCR TESTS** Sanger & Next Generation Sequencing Techniques In Current Use Worldwide
- **SECOND LEVEL PROCESSING** Required By Current Variant Detection Tools
- **INCREASE IN COMPLEXITY** Requires Specialized Staff And Instrumentation
- **ONLY REPRESENTATIVE SAMPLING FOR VARIANTS** Due To Increased Time & Complexities

OACP DEVELOPED A **PATENT PENDING** RT-PCR PLATFORM

USD > 18B MARKET
OPPORTUNITY



INFECTIOUS DISEASES
DETECTION
INCLUDING COVID-19



PRECISION MEDICINE
FOR **CANCER**


COMPETITION

	 OaCP	 ThermoFisher SCIENTIFIC	 QIAGEN
FAST PCR TEST	✓		
WIDE COMPATIBILITY	✓	✓	
COST-EFFECTIVE	✓		


OACP COVID-19 DETECTION KIT WITH VARIANT DETECTION

< 1HOUR SINGLE STEP PCR PROCESS


- DETECTS SIMULTENOUSLY COVID -19 + MAJOR VARIANTS
 - SIMPLIFIED APPROACH, REPLACE SEQUENCING,
 - DRAMATICALLY REDUCES TIME, COST AND COMPLEXITY



MILESTONES



Gross Sales €



	Gross Sales
2019	€ 94,000
2020	€ 194,000
2021	€ 1,037,000
2022	€ 2,620,000
2023	€ 5,670,000

SALES PIPELINE 2021

Deal in progress:

- 1) A large distributor for **1 M** Covid Kits per month (At contract stage).
- 2) Italian Government requiring up to **500K** Covid Kits per 6 months (At contract Stage).
- 3) A large laboratory chain is looking for **1M** Covid Kits/ year.
- 4) Further negotiations with other distributors and customers

STRATEGIC OBJECTIVES

SECURING ADDITIONAL FUNDING MECHANISMS TO
SUPPORT GROWTH

STRATEGIC PARTNERSHIPS.

OUT-LICENSING & OEM ARRANGEMENTS.

REGIONAL DISTRIBUTORS & LABORATORY PARTNERS

TRADE SALE WITHIN 3 YEARS



NOVEL & APPROVED REAGENTS FOR CANCER & COVID 19 DETECTION

**LESS TIME FOR
DIAGNOSIS
MORE TIME FOR LIFE**



CEO@OACP.IT
WWW.OACP.IT



@OaCPIELTD



OaCP

ONCOLOGY DIAGNOSTIC REAGENTS

- 50% COST REDUCTION & 97% TIME REDUCTION
- **CE-IVD**
- STRONG IP

COVID PCR TEST PLATFORM FOR VARIANTS

- PCR TIME: 45 MINUTES
- **4 TESTS IN 1 TUBE**
- FOR COMMON COVID + MAIN VARIANTS
- **CE-IVD**